Cargando…
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas
The optimal timing for administering high-dose methotrexate (HDMTX) when combined with (R)CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone, with/without rituximab) is unclear. Recent data showed that the administration of prophylactic HDMTX before day 10 of R- CHOP may lead to fewer trea...
Autores principales: | Fleming, Megan, Huang, Ying, Dotson, Emily, Bond, David A., Reneau, John, Epperla, Narendranath, Alinari, Lapo, Brammer, Jonathan, Christian, Beth A., Baiocchi, Robert A., Maddocks, Kami, Sawalha, Yazeed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791577/ https://www.ncbi.nlm.nih.gov/pubmed/34788387 http://dx.doi.org/10.1182/bloodadvances.2021005999 |
Ejemplares similares
-
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study
por: Fleming, Megan, et al.
Publicado: (2022) -
Treatment of primary mediastinal B-cell lymphoma with dose-adjusted REPOCH during pregnancy
por: Annunzio, Kaitlin, et al.
Publicado: (2022) -
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents
por: Faisal, Muhammad Salman, et al.
Publicado: (2023) -
P1071: COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY
por: Bond, David, et al.
Publicado: (2023) -
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with Waldenstrom macroglobulinemia
por: Nalin, Ansel, et al.
Publicado: (2023)